Full-text search across primary regulatory records, analytical lab audits, and evidence-led pharmacology guides.
News WireThe July 23 PCAC vote recommended six peptides for human compounding despite career scientists citing absent safety data. The decision amplified demand across informal markets, including pet-care channels where no dosing evidence exists.
GuideGHRP-2 and GHRP-6 are synthetic peptides that trigger growth hormone release by acting on the ghrelin receptor. Despite documented physiological activity, neither holds FDA approval, and both are prohibited by WADA under Category S2.
News WireWeightlifter Jara MacDermott accepted a two-year period of ineligibility on August 20, 2026, for testing positive for canrenone, amphetamine, and testosterone. The announcement arrives eight days after USADA publicly flagged BPC-157 as a.
News WireSocial media celebrates the Wolverine Stack as a shortcut to rapid injury healing. Stanford Medicine and AMA experts counter that no controlled human trial has tested BPC-157 and TB-500 together, and the FDA's Category 2 designation bars.
GuideThe NCAA explicitly bans peptide hormones, growth factors, and related substances. This prohibition applies year-round. A positive test for BPC-157 or MK-677 results in a minimum one-year loss of eligibility, with very narrow exceptions.
GuideWhile semaglutide and insulin are approved drugs with validated safety data, peptides like BPC-157 and TB-500 are not. Understanding the difference between drug approval and compounding eligibility is critical for patient safety.
News WireMike McKnight told Cam Hanes' podcast audience that BPC-157 healed his herniated disc and let him cancel surgery. USADA prohibits the peptide at all times. The FDA just voted to let compounding pharmacies make it.
GuideThe 'Wolverine Stack' has moved from online forums to physical exam rooms, with providers in Florida, Texas, and Connecticut marketing a combined BPC-157 and TB-500 protocol. While preclinical data supports individual tissue repair.